Trial Profile

The Effect of Neprilysin on Plasma Concentrations of Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 19 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sacubitril/valsartan (Primary) ; Sitagliptin (Primary) ; Valsartan (Primary)
Indications Hyperglycaemia; Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms NEPT2D

Most Recent Events

01 Oct 2022 Results published in the Diabetes, Obesity and Metabolism
04 May 2021 Status changed from recruiting to completed.
25 Sep 2020 Results (n=8) assessing effects of a single dose sacubitril/valsartan on postprandial glucose control in patients with T2D patients presented at the 56th Annual Meeting of the European Association for the Study of Diabetes

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com